Copyright Reports & Markets. All rights reserved.

Global Tyrosine Kinase JAK Inhibitors Market Growth 2019-2024

Request for Sample of this report
Buy now

Table of Contents

    2019-2024 Global Tyrosine Kinase JAK Inhibitors Consumption Market Report

      1 Scope of the Report

      • 1.1 Market Introduction
      • 1.2 Research Objectives
      • 1.3 Years Considered
      • 1.4 Market Research Methodology
      • 1.5 Economic Indicators
      • 1.6 Currency Considered

      2 Executive Summary

      • 2.1 World Market Overview
        • 2.1.1 Global Tyrosine Kinase JAK Inhibitors Consumption 2014-2024
        • 2.1.2 Tyrosine Kinase JAK Inhibitors Consumption CAGR by Region
      • 2.2 Tyrosine Kinase JAK Inhibitors Segment by Type
        • 2.2.1 Tofacitinib
        • 2.2.2 Ruxolitinib
        • 2.2.3 Baricitinib
      • 2.3 Tyrosine Kinase JAK Inhibitors Consumption by Type
        • 2.3.1 Global Tyrosine Kinase JAK Inhibitors Consumption Market Share by Type (2014-2019)
        • 2.3.2 Global Tyrosine Kinase JAK Inhibitors Revenue and Market Share by Type (2014-2019)
        • 2.3.3 Global Tyrosine Kinase JAK Inhibitors Sale Price by Type (2014-2019)
      • 2.4 Tyrosine Kinase JAK Inhibitors Segment by Application
        • 2.4.1 Rheumatoid Arthritis (RA)
        • 2.4.2 Polycythemia Vera (PCV)
        • 2.4.3 Myelofibrosis (MF)
        • 2.4.4 Others
      • 2.5 Tyrosine Kinase JAK Inhibitors Consumption by Application
        • 2.5.1 Global Tyrosine Kinase JAK Inhibitors Consumption Market Share by Application (2014-2019)
        • 2.5.2 Global Tyrosine Kinase JAK Inhibitors Value and Market Share by Application (2014-2019)
        • 2.5.3 Global Tyrosine Kinase JAK Inhibitors Sale Price by Application (2014-2019)

      3 Global Tyrosine Kinase JAK Inhibitors by Players

      • 3.1 Global Tyrosine Kinase JAK Inhibitors Sales Market Share by Players
        • 3.1.1 Global Tyrosine Kinase JAK Inhibitors Sales by Players (2017-2019)
        • 3.1.2 Global Tyrosine Kinase JAK Inhibitors Sales Market Share by Players (2017-2019)
      • 3.2 Global Tyrosine Kinase JAK Inhibitors Revenue Market Share by Players
        • 3.2.1 Global Tyrosine Kinase JAK Inhibitors Revenue by Players (2017-2019)
        • 3.2.2 Global Tyrosine Kinase JAK Inhibitors Revenue Market Share by Players (2017-2019)
      • 3.3 Global Tyrosine Kinase JAK Inhibitors Sale Price by Players
      • 3.4 Global Tyrosine Kinase JAK Inhibitors Manufacturing Base Distribution, Sales Area, Product Types by Players
        • 3.4.1 Global Tyrosine Kinase JAK Inhibitors Manufacturing Base Distribution and Sales Area by Players
        • 3.4.2 Players Tyrosine Kinase JAK Inhibitors Products Offered
      • 3.5 Market Concentration Rate Analysis
        • 3.5.1 Competition Landscape Analysis
        • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
      • 3.6 New Products and Potential Entrants
      • 3.7 Mergers & Acquisitions, Expansion

      4 Tyrosine Kinase JAK Inhibitors by Regions

      • 4.1 Tyrosine Kinase JAK Inhibitors by Regions
        • 4.1.1 Global Tyrosine Kinase JAK Inhibitors Consumption by Regions
        • 4.1.2 Global Tyrosine Kinase JAK Inhibitors Value by Regions
      • 4.2 Americas Tyrosine Kinase JAK Inhibitors Consumption Growth
      • 4.3 APAC Tyrosine Kinase JAK Inhibitors Consumption Growth
      • 4.4 Europe Tyrosine Kinase JAK Inhibitors Consumption Growth
      • 4.5 Middle East & Africa Tyrosine Kinase JAK Inhibitors Consumption Growth

      5 Americas

      • 5.1 Americas Tyrosine Kinase JAK Inhibitors Consumption by Countries
        • 5.1.1 Americas Tyrosine Kinase JAK Inhibitors Consumption by Countries (2014-2019)
        • 5.1.2 Americas Tyrosine Kinase JAK Inhibitors Value by Countries (2014-2019)
      • 5.2 Americas Tyrosine Kinase JAK Inhibitors Consumption by Type
      • 5.3 Americas Tyrosine Kinase JAK Inhibitors Consumption by Application
      • 5.4 United States
      • 5.5 Canada
      • 5.6 Mexico
      • 5.7 Key Economic Indicators of Few Americas Countries

      6 APAC

      • 6.1 APAC Tyrosine Kinase JAK Inhibitors Consumption by Countries
        • 6.1.1 APAC Tyrosine Kinase JAK Inhibitors Consumption by Countries (2014-2019)
        • 6.1.2 APAC Tyrosine Kinase JAK Inhibitors Value by Countries (2014-2019)
      • 6.2 APAC Tyrosine Kinase JAK Inhibitors Consumption by Type
      • 6.3 APAC Tyrosine Kinase JAK Inhibitors Consumption by Application
      • 6.4 China
      • 6.5 Japan
      • 6.6 Korea
      • 6.7 Southeast Asia
      • 6.8 India
      • 6.9 Australia
      • 6.10 Key Economic Indicators of Few APAC Countries

      7 Europe

      • 7.1 Europe Tyrosine Kinase JAK Inhibitors by Countries
        • 7.1.1 Europe Tyrosine Kinase JAK Inhibitors Consumption by Countries (2014-2019)
        • 7.1.2 Europe Tyrosine Kinase JAK Inhibitors Value by Countries (2014-2019)
      • 7.2 Europe Tyrosine Kinase JAK Inhibitors Consumption by Type
      • 7.3 Europe Tyrosine Kinase JAK Inhibitors Consumption by Application
      • 7.4 Germany
      • 7.5 France
      • 7.6 UK
      • 7.7 Italy
      • 7.8 Russia
      • 7.9 Spain
      • 7.10 Key Economic Indicators of Few Europe Countries

      8 Middle East & Africa

      • 8.1 Middle East & Africa Tyrosine Kinase JAK Inhibitors by Countries
        • 8.1.1 Middle East & Africa Tyrosine Kinase JAK Inhibitors Consumption by Countries (2014-2019)
        • 8.1.2 Middle East & Africa Tyrosine Kinase JAK Inhibitors Value by Countries (2014-2019)
      • 8.2 Middle East & Africa Tyrosine Kinase JAK Inhibitors Consumption by Type
      • 8.3 Middle East & Africa Tyrosine Kinase JAK Inhibitors Consumption by Application
      • 8.4 Egypt
      • 8.5 South Africa
      • 8.6 Israel
      • 8.7 Turkey
      • 8.8 GCC Countries

      9 Market Drivers, Challenges and Trends

      • 9.1 Market Drivers and Impact
        • 9.1.1 Growing Demand from Key Regions
        • 9.1.2 Growing Demand from Key Applications and Potential Industries
      • 9.2 Market Challenges and Impact
      • 9.3 Market Trends

      10 Marketing, Distributors and Customer

      • 10.1 Sales Channel
        • 10.1.1 Direct Channels
        • 10.1.2 Indirect Channels
      • 10.2 Tyrosine Kinase JAK Inhibitors Distributors
      • 10.3 Tyrosine Kinase JAK Inhibitors Customer

      11 Global Tyrosine Kinase JAK Inhibitors Market Forecast

      • 11.1 Global Tyrosine Kinase JAK Inhibitors Consumption Forecast (2019-2024)
      • 11.2 Global Tyrosine Kinase JAK Inhibitors Forecast by Regions
        • 11.2.1 Global Tyrosine Kinase JAK Inhibitors Forecast by Regions (2019-2024)
        • 11.2.2 Global Tyrosine Kinase JAK Inhibitors Value Forecast by Regions (2019-2024)
        • 11.2.3 Americas Consumption Forecast
        • 11.2.4 APAC Consumption Forecast
        • 11.2.5 Europe Consumption Forecast
        • 11.2.6 Middle East & Africa Consumption Forecast
      • 11.3 Americas Forecast by Countries
        • 11.3.1 United States Market Forecast
        • 11.3.2 Canada Market Forecast
        • 11.3.3 Mexico Market Forecast
        • 11.3.4 Brazil Market Forecast
      • 11.4 APAC Forecast by Countries
        • 11.4.1 China Market Forecast
        • 11.4.2 Japan Market Forecast
        • 11.4.3 Korea Market Forecast
        • 11.4.4 Southeast Asia Market Forecast
        • 11.4.5 India Market Forecast
        • 11.4.6 Australia Market Forecast
      • 11.5 Europe Forecast by Countries
        • 11.5.1 Germany Market Forecast
        • 11.5.2 France Market Forecast
        • 11.5.3 UK Market Forecast
        • 11.5.4 Italy Market Forecast
        • 11.5.5 Russia Market Forecast
        • 11.5.6 Spain Market Forecast
      • 11.6 Middle East & Africa Forecast by Countries
        • 11.6.1 Egypt Market Forecast
        • 11.6.2 South Africa Market Forecast
        • 11.6.3 Israel Market Forecast
        • 11.6.4 Turkey Market Forecast
        • 11.6.5 GCC Countries Market Forecast
      • 11.7 Global Tyrosine Kinase JAK Inhibitors Forecast by Type
      • 11.8 Global Tyrosine Kinase JAK Inhibitors Forecast by Application

      12 Key Players Analysis

      • 12.1 Pfizer
        • 12.1.1 Company Details
        • 12.1.2 Tyrosine Kinase JAK Inhibitors Product Offered
        • 12.1.3 Pfizer Tyrosine Kinase JAK Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.1.4 Main Business Overview
        • 12.1.5 Pfizer News
      • 12.2 Incyte
        • 12.2.1 Company Details
        • 12.2.2 Tyrosine Kinase JAK Inhibitors Product Offered
        • 12.2.3 Incyte Tyrosine Kinase JAK Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.2.4 Main Business Overview
        • 12.2.5 Incyte News
      • 12.3 Novartis
        • 12.3.1 Company Details
        • 12.3.2 Tyrosine Kinase JAK Inhibitors Product Offered
        • 12.3.3 Novartis Tyrosine Kinase JAK Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.3.4 Main Business Overview
        • 12.3.5 Novartis News
      • 12.4 Eli Lilly
        • 12.4.1 Company Details
        • 12.4.2 Tyrosine Kinase JAK Inhibitors Product Offered
        • 12.4.3 Eli Lilly Tyrosine Kinase JAK Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.4.4 Main Business Overview
        • 12.4.5 Eli Lilly News
      • 12.5 Gilead
        • 12.5.1 Company Details
        • 12.5.2 Tyrosine Kinase JAK Inhibitors Product Offered
        • 12.5.3 Gilead Tyrosine Kinase JAK Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.5.4 Main Business Overview
        • 12.5.5 Gilead News
      • 12.6 Sanofi
        • 12.6.1 Company Details
        • 12.6.2 Tyrosine Kinase JAK Inhibitors Product Offered
        • 12.6.3 Sanofi Tyrosine Kinase JAK Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.6.4 Main Business Overview
        • 12.6.5 Sanofi News
      • 12.7 Galapagos
        • 12.7.1 Company Details
        • 12.7.2 Tyrosine Kinase JAK Inhibitors Product Offered
        • 12.7.3 Galapagos Tyrosine Kinase JAK Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.7.4 Main Business Overview
        • 12.7.5 Galapagos News
      • 12.8 AbbVie
        • 12.8.1 Company Details
        • 12.8.2 Tyrosine Kinase JAK Inhibitors Product Offered
        • 12.8.3 AbbVie Tyrosine Kinase JAK Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.8.4 Main Business Overview
        • 12.8.5 AbbVie News
      • 12.9 Vertex
        • 12.9.1 Company Details
        • 12.9.2 Tyrosine Kinase JAK Inhibitors Product Offered
        • 12.9.3 Vertex Tyrosine Kinase JAK Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.9.4 Main Business Overview
        • 12.9.5 Vertex News
      • 12.10 Teva
        • 12.10.1 Company Details
        • 12.10.2 Tyrosine Kinase JAK Inhibitors Product Offered
        • 12.10.3 Teva Tyrosine Kinase JAK Inhibitors Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.10.4 Main Business Overview
        • 12.10.5 Teva News
      • 12.11 Astellas Pharma
      • 12.12 Celgene
      • 12.13 CTI BioPharma

      13 Research Findings and Conclusion

      Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway.

      These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis. There is interest in their use for various skin conditions. JAK3 inhibitors are attractive as a possible treatment of various autoimmune diseases since its functions is mainly restricted to lymphocytes. Development for a selective JAK3 inhibitors are ongoing.

      In the report, we only count drugs for human beings. And the 1 unit is 1 tablet.

      Tyrosine Kinase JAK Inhibitors is widely used in Rheumatoid Arthritis (RA), Polycythemia Vera (PCV) and Myelofibrosis (MF). The most proportion of Tyrosine Kinase JAK Inhibitors is for Rheumatoid Arthritis (RA), and the proportion in 2017 is about 37%.
      North America is the largest consumption place, with a consumption market share nearly 56% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 39%.

      According to this study, over the next five years the Tyrosine Kinase JAK Inhibitors market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Tyrosine Kinase JAK Inhibitors business, shared in Chapter 3.

      This report presents a comprehensive overview, market shares, and growth opportunities of Tyrosine Kinase JAK Inhibitors market by product type, application, key manufacturers and key regions and countries.

      This study considers the Tyrosine Kinase JAK Inhibitors value and volume generated from the sales of the following segments:

      Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
      Tofacitinib
      Ruxolitinib
      Baricitinib
      Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
      Rheumatoid Arthritis (RA)
      Polycythemia Vera (PCV)
      Myelofibrosis (MF)
      Others

      This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
      Americas
      United States
      Canada
      Mexico
      Brazil
      APAC
      China
      Japan
      Korea
      Southeast Asia
      India
      Australia
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Middle East & Africa
      Egypt
      South Africa
      Israel
      Turkey
      GCC Countries

      The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
      Pfizer
      Incyte
      Novartis
      Eli Lilly
      Gilead
      Sanofi
      Galapagos
      AbbVie
      Vertex
      Teva
      Astellas Pharma
      Celgene
      CTI BioPharma

      In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

      Research objectives
      To study and analyze the global Tyrosine Kinase JAK Inhibitors consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
      To understand the structure of Tyrosine Kinase JAK Inhibitors market by identifying its various subsegments.
      Focuses on the key global Tyrosine Kinase JAK Inhibitors manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
      To analyze the Tyrosine Kinase JAK Inhibitors with respect to individual growth trends, future prospects, and their contribution to the total market.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      To project the consumption of Tyrosine Kinase JAK Inhibitors submarkets, with respect to key regions (along with their respective key countries).
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
      To strategically profile the key players and comprehensively analyze their growth strategies.

      Buy now